I en klinisk undersøgelse med ReFacto AF hos tidligere behandlede patienter (PTP’ er) var incidensen af faktor VIII- inhibitorer det primære slutmål for sikkerhed.
In a clinical study with ReFacto AF in previously treated patients (PTPs), the incidence of factor VIII inhibitors was the primary safety endpoint.